Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients with the MELAS syndrome experience devastating mental impairment. This study will evaluate the effectiveness of the drug dichloroacetate (DCA) to reduce the symptoms of MELAS.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Criteria

Inclusion Criteria

• A3243G mtDNA point mutation or maternally related to someone who has the mutation

• Symptomatic with MELAS, including previous seizure or stroke

• Certain laboratory values

• Ability to comply with the study protocol